Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: Current status of dopamine system vulnerability in NeuroAIDS

Neuroscience and Biobehavioral Reviews

Volumn 32, Issue 5, 2008, Pages 883-909

  Ferris, Mark J ^a   Mactutus, Charles F ^a   Booze, Rosemarie M ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cocaine; DAT; Dopamine; gp120; HAD; HIV; Methamphetamine; NeuroAIDS; Psychostimulant; Review; Tat

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; COCAINE; EPIGALLOCATECHIN GALLATE; ESTRADIOL; FULVESTRANT; GLYCOPROTEIN GP 120; METHAMPHETAMINE; PROGESTERONE; PSYCHOSTIMULANT AGENT; STEROID 5ALPHA REDUCTASE; TAMOXIFEN; TRANSACTIVATOR PROTEIN;

APOPTOSIS; BASAL GANGLION; BRAIN; CENTRAL NERVOUS SYSTEM FUNCTION; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG ACTIVITY; DRUG MECHANISM; GRAY MATTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; WHITE MATTER;

ANIMALS; BRAIN; COCAINE; DOPAMINE; HIV; HIV INFECTIONS; HUMANS; METHAMPHETAMINE; NERVOUS SYSTEM DISEASES; NEURAL PATHWAYS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; SUBSTANCE-RELATED DISORDERS;

EID: 44449094924     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2008.01.004     Document Type: Review

References (327)

1. Achim C.L., Wang R., Miners D.K., and Wiley C.A. Brain viral burden in HIV infection. J. Neuropathol. Exp. Neurol. 53 (1994) 284-294
2. Aksenova M.V., Silvers J.M., Aksenov M.Y., Nath A., Ray P.D., Mactutus C.F., and Booze R.M. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci. Lett. 395 (2006) 235-239
3. Aksenova M.V., Aksenov M.Y., Mactutus C.F., and Booze R.M. Cell culture models of oxidative stress and injury in the central nervous system. Curr. Neurovasc. Res. 2 (2005) 73-89
4. Aksenov M.Y., Aksenova M.V., Nath A., Ray P.D., Mactutus C.F., and Booze R.M. Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology 27 (2006) 217-228
5. Aksenov M.Y., Hasselrot U., Wu G., Nath A., Anderson C., Mactutus C.F., and Booze R.M. Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res. 987 (2003) 1-9
6. Aksenov M.Y., Hasselrot U., Bansal A.K., Guanghan W., Nath A., Anderson C., Mactutus C.F., and Booze R.M. Oxidative damage induced by the injection of HIV-1 Tat protein in the rat striatum. Neurosci. Lett. 305 (2001) 5-8
7. Allard J.P., Aghdassi E., Chau J., Tam C., Kovacs C.M., Salit I.E., and Walmsley S.L. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS 12 (1998) 1653-1659
8. Ambrosio S.R., Tella S.R., Goldberg S.R., Schindler C.W., Erzouki H., and Elmer G.I. Cardiovascular effects of cocaine during operant cocaine self-administration. Eur. J. Pharmacol. 315 (1996) 43-51
9. An S.F., Groves M., Gray F., and Scaravilli F. Early entry and widespread cellular involvement of HIV-1 DNA in brain of HIV-1 positive asymptomatic individuals. J. Neuropathol. Exp. Neurol. 58 (1999) 1156-1162
10. Anderson S.M., and Pierce R.C. Cocaine-induced alterations in dopamine receptor signaling: implications for reinforcement and reinstatement. Pharmacol. Ther. 106 (2005) 389-403
11. Anthony I.C., Ramage S.N., Carnie F.W., Simmonds P., and Bell J.E. Influence of HAART on HIV-related CNS disease and neuroinflammation. J. Neuropathol. Exp. Neurol. 64 (2005) 529-536
12. Arendt G., Hefter H., Hilperath F., von Giesen H.J., Strohmeyer G., and Freund H.J. Motor analysis predicts progression in HIV-associated brain disease. J. Neurol. Sci. 123 (1994) 180-185
13. Arendt G., Hefter H., Elsing C., Strohmeyer G., and Freund H.J. Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit. J. Neurol. 237 (1990) 362-368
14. Avants S.K., Margolin A., Warburton L.A., Hawkins K.A., and Shi J. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am. J. Addict. 10 (2001) 69-78
15. Avgeropoulos N., Kelley B., Middaugh L., Arrigo S., Persidsky Y., Gendelman H.E., and Tyor W.R. SCID mice with HIV encephalitis develop behavioral abnormalities. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18 (1998) 13-20
16. Aylward E.H., Brettschneider P.D., McArthur J.C., Harris G.J., Schlaepfer T.E., Henderer J.D., Barta P.E., Tien A.Y., and Pearlson G.D. Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. Am. J. Psychiatry 152 (1995) 987-994
17. Aylward E.H., Henderer J.D., McArthur J.C., Brettschneider P.D., Harris G.J., Barta P.E., and Pearlson G.D. Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging. Neurology 43 (1993) 2099-2104
18. Bagetta G., Corasaniti M.T., Berliocchi L., Navarra M., Finazzi-Agro A., and Nistico G. HIV-1 gp120 produces DNA fragmentation in the cerebral cortex of the rat. Biochem. Biophys. Res. Commun. 211 (1995) 130-136
19. Baggaley R.F., Boily M.C., White R.G., and Alary M. Risk of HIV-1 transmission for parental exposure and blood transfusion: a systematic review and meta-analysis. AIDS 20 (2006) 805-812
20. Banks W.A., Ercal N., and Price T.O. The blood-brain barrier and neuroAIDS. Curr. HIV Res. 4 (2006) 259-266
21. Banks W.A., Robinson S.M., and Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp. Neurol. 193 (2005) 218-227
22. Bansal A.K., Mactutus C.F., Nath A., Anderson C., and Booze R.M. Intravenous cocaine abuse: a rodent model for potential interactions with HIV proteins. Adv. Exp. Med. Biol. 493 (2001) 241-245
23. Bansal A.K., Mactutus C.F., Nath A., Maragos W., Hauser K.F., and Booze R.M. Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res. 879 (2000) 42-49
24. Barks J.D., Sun R., Malinak C., and Silverstein F.S. Gp120, and HIV-1 protein, increases susceptibility to hypoglycemic and ischemic brain injury in prenatal rats. Exp. Neurol. 132 (1995) 123-133
25. Bartzokis G., Beckson M., Lu P.H., Edwards N., Rapoport R., Wiseman E., and Bridge P. Age-related brain volume reductions in amphetamine and cocaine addicts and normal controls: implications for addiction research. Psychiatr. Res. 98 (2000) 93-102
26. Bartzokis G., Goldstein I.B., Hance D.B., Beckson M., Shapiro D., Lu P.H., Edwards N., Mintz J., and Bridge P. The incidence of T2-weighted MR imaging signal abnormalities in the brain of cocaine-dependent patients in age-related and region-specific. Am. J. Neuroradiol. 20 (1999) 1628-1635
27. Baucum A.J., Rau K.S., Riddle E.L., Hanson G.R., and Fleckenstein A.E. Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J. Neurosci. 24 (2004) 3436-3443
28. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271 (1996) C1424-C1437
29. Bell J.E. An update on the neuropathology of HIV in the HAART era. Histopathology 45 (2004) 549-559
30. Bell J.E., Brettle R.P., Chiswick A., and Simmonds P. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS: effect of neocortical involvement. Brain 121 (1998) 2043-2052
31. Bennett B.A., Hyde C.E., Pecora J.R., and Clodfelter J.E. Long-term cocaine administration is not neurotoxic to cultured fetal mesencephalic dopamine neurons. Neurosci. Lett. 153 (1993) 210-214
32. Berger J.R., and Arednt G. HIV dementia: the role of the basal ganglia and dopaminergic systems. J. Psychopharm. 14 (2000) 214-221
33. Berger J.R., and Nath A. HIV dementia and the basal ganglia. Intervirology 40 (1997) 122-131
34. Berger J.R., Kumar M., Kumar A., Fernandez J., and Levin B. Cerebrospinal fluid dopamine in HIV-1 infection. J. AIDS 8 (1994) 67-71
35. Beveridge T.J., Smith H.R., Nader M.A., and Porrino L.J. Functional effects of cocaine self-administration in primate brain regions regulating cardiovascular function. Neurosci. Lett. 370 (2004) 201-205
36. Bolla K.I., Cadet J.L., and London E.D. The neuropsychiatry of chronic cocaine abuse. J. Neuropsychiatr. Clin. Neurosci. 10 (1998) 280-289
37. Bouwman F.H., Skolasky R.L., Hes D., Selnes O.A., Glass J.D., Nance-Sproson T.E., Royal W., Dal Pan G.J., and McArthur J.C. Variable progression of HIV-associated dementia. Neurology 50 (1998) 1814-1820
38. Boven L.A., Middel J., Breij E.C., Schotte D., Verhoef J., Soderland C., and Nottet H.S. Interactions between HIV-infected monocyte-derived macrophages and human brain microvascular endothelial cells result in increased expression of CC chemokines. J. Neurovirol. 6 (2000) 382-389
39. Boven L.A., Middel J., Verhoef J., De Groot C.J., and Nottet H.S. Monocyte infiltration is highly associated with loss of tight junction protein zonula occludens in HIV-1 associated dementia. Neuropathol. Appl. Neurobiol. 26 (2000) 356-360
40. Boven L.A., Gomes L., Hery C., Gray F., Verhoef J., Portegies P., Tardieu M., and Nottet H.S. Increased peroxynitrite activity in AIDS dementia complex: implications for the neuropathogenesis of HIV-1 infection. J. Immunol. 162 (1999) 4319-4327
41. Brenneman D.E., Westbrook G.L., Fitzgerald S.P., Ennist D.L., Elkins K.L., Ruff M.R., and Pert C.B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335 (1998) 639-642
42. Brown J.M., Hanson G.R., and Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296 (2001) 762-767
43. Bruce-Keller A.J., Chauhan A., Dimayuga F.O., Gee J., Keller J.N., and Nath A. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J. Neurosci. 23 (2003) 8417-8422
44. Bubar M.J., and Cunningham K.A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr. Top. Med. Chem. 6 (2006) 1971-1985
45. Büttner A., Mall G., Penning R., Sachs H., and Weis S. The neuropathology of cocaine abuse. Leg. Med. (Tokyo) 5 (2003) S240-S242
46. Burkala E., West J.T., He J., Petito C.K., and Wood C. The choroid plexus and viral entry into the brain. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 155-161
47. Cadet J.L., and Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 32 (1998) 117-131
48. Cadet J.L., and Bolla K.I. Chronic cocaine use as a neuropsychiatric syndrome: a model for debate. Synapse 22 (1996) 28-34
49. Cadet J.L., Sheng P., Ali S., Rothman R., Carlson E., and Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62 (1994) 380-383
50. Cass W.A., Harned M.E., Peters L.E., Nath A., and Maragos W.F. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res. 984 (2003) 133-142
51. Cass W.A., Zahniser N.R., Flach K.A., and Gerhardt G.A. Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J. Neurochem. 61 (1993) 2269-2278
52. Cepeda C., and Levine M.S. Where do you think you are going? The NMDA-D1 receptor trap. Sci. STKE 2006 (2006) e20
53. Cervinski M.A., Foster J.D., and Vaughan R.A. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J. Biol. Chem. 280 (2005) 40442-40449
54. Chang L., Ernst T., Speck O., and Grob C.S. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am. J. Psychiatry 162 (2005) 361-369
55. Chang L., Speck O., Miller E.N., Braun J., Jovicich J., Koch C., Itti K., and Ernst T. Neural correlates of attention and working memory deficits in HIV patients. Neurology 57 (2001) 1001-1007
56. Chauhan A., Turchan J., Pocernich C., Bruce-Keller A., Roth S., Butterfield D.A., Major E.O., and Nath A. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 278 (2003) 13512-13519
57. Chi L., and Reith M.E. Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J. Pharmacol. Exp. Ther. 307 (2003) 729-736
58. Cloak C.C., Chang L., and Ernst T. Increased frontal white matter diffusion is associated with glial metabolites and psychomotor slowing in HIV. J. Neuroimmunol. 157 (2004) 147-152
59. Cloak C.C., Chang L., Ernst T., Barr M.C., Huitron-Resendiz S., Sanchez-Alavez M., Phillips T.R., and Henriksen S. Methamphetamine and AIDS: 1HMRS studies in a feline model of human disease. J. Neuroimmunol. 147 (2004) 16-20
60. Conant K., St Hillaire C., Anderson C., Galey D., Wang J., and Nath A. Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. J. Neurovirol. 10 (2004) 21-28
61. Conant K., McArthur J.C., Griffin D.E., Sjulson L., Wahl L.M., and Irani D.N. Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann. Neurol. 46 (1999) 391-398
62. Cook-Easterwood J., Middaugh L.D., Griffin III W.C., Khan I., and Tyor W.R. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp. Neurol. 205 (2007) 506-512
63. Corasaniti M.T., Amantea D., Russo R., Piccirilli S., Leta A., Corazzari M., Nappi G., and Bagetta G. 18beta-Estradiol reduces neuronal apoptosis induced by HIV-1 gp120 in the neocortex of rat. Neurotoxicology 26 (2005) 893-903
64. Corasaniti M.T., Rotiroti D., Nappi G., and Bagetta G. Neurobiological mediators of neuronal apoptosis in experimental neuroAIDS. Toxicol. Lett. 139 (2003) 199-206
65. Cowell R.M., Kantor L., Hewlett G.H., Frey K.A., and Gnegy M.E. Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur. J. Pharmacol. 389 (2000) 59-65
66. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
67. Cubells J.F., Rayport S., Rajndron G., and Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endoxydic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14 (1994) 2260-2271
68. Czlonkowska A., Ciesielska A., and Joniec I. Influence of estrogens on neurodegenerative processes. Med. Sci. Monit. 9 (2003) 247-256
69. Dal Pan G.J., McArthur J.H., Aylward E., Selnes O.A., Nance-Sproson T.E., Kumar A.J., Mellits E.D., and McArthur J.C. Patterns of cerebral atrophy in HIV-1 infected individuals: results of a quantitative MRI analysis. Neurology 42 (1992) 2125-2130
70. Dallasta L.M., Pisarov L.A., Esplen J.E., Werley J.V., Moses A.V., Nelson J.A., and Achim C.L. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 155 (1999) 1915-1927
71. D'Aversa T.G., Eugenin E.A., and Berman J.W. NeuroAIDS: contributions of the human immunodeficiency virus-1 Tat and gp120 as well as CD40 to microflial activation. J. Neurosci. Res. 81 (2005) 436-446
72. Daws L.C., Callaghan P.D., Moron J.A., Kahlig K.M., Shippenberg T.S., Javitch J.A., and Galli A. Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem. Biophys. Res. Commun. 290 (2002) 1545-1550
73. Dawson V.L., Dawson T.M., Uhl G.R., and Snyder S.H. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 3256-3259
74. DeArmond S.J., Fusco M.M., and Dewey M.M. Structure of the Human Brain: A Photographic Atlas. 3rd ed. (1989), Oxford University Press, New York
75. Dey S., Mactutus C.F., Booze R.M., and Snow D.M. Cocaine exposure in vitro induces apoptosis in fetal locus coeruleus neurons by altering the Bax/Bcl-2 ratio and through caspase-3 apoptotic signaling. Neuroscience 144 (2007) 509-521
76. Dey S., Mactutus C.F., Booze R.M., and Snow D.M. Specificity of prenatal cocaine on inhibition of locus coeruleus neurite outgrowth. Neuroscience 139 (2006) 899-907
77. Di Rocco A., Bottiglieri T., Dorfman D., Werner P., Morrison C., and Simpson D. Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin. Neuropharmacol. 23 (2000) 190-194
78. Di Stefano M., Sabri F., and Chiodi F. HIV-1 structural and regulatory proteins and neurotoxicity. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 49-56
79. Diop A.G., Lesort M., Esclaire F., Dumas M., and Hugon J. Tetrodotoxin blocks HIV coat protein (gp120) toxicity in primary neuronal cultures. Neurosci. Lett. 165 (1994) 187-190
80. Doolen S., and Zahniser N.R. Conventional protein kinase C isoforms regulate human dopamine transporter activity in Xenopus oocytes. FEBS Lett. 516 (2002) 187-190
81. Dwoskin L.P., Rauhut A.S., King-Pospisil K.A., and Bardo M.T. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 12 (2006) 178-207
82. Edelstein H., and Knight R.T. Severe Parkinsonism in two AIDS patients taking prochlorperazine. Lancet 2 (1987) 341-342
83. Edwards S., Whisler K.N., Fuller D.C., Orsulak P.J., and Self D.W. Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. Neuropsychopharmacology 32 (2007) 354-366
84. Eisch A.J., O'Dell S.J., and Marshall J.F. Striatal and cortical NMDA receptors are altered by a neurotoxic regimen of methamphetamine. Synapse 22 (1996) 217-225
85. Eisch A.J., Gaffney M., Weihmuller F.B., O'Dell S.J., and Marshall J.F. Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res. 598 (1992) 321-326
86. Ellis R.J., Merdes A., Masliah E., and Langford T.D. Clinical-neuropathological correlation in HIV in the era of highly active antiretroviral therapy. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 799-810
87. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., Wingfield P., and Gallo R.C. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67 (1993) 277-287
88. Ernst T., and Chang L. Effect of aging on brain metabolism in antiretroviral-naive HIV patients. AIDS 18 (2004) 61-67
89. Ernst T., Chang L., Jovicich J., Ames N., and Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 59 (2002) 1343-1349
90. Eshleman A.J., Henningsen R.A., Neve K.A., and Janowsky A. Release of dopamine via the human transporter. Mol. Pharmacol. 45 (1994) 312-316
91. Everall I.P., Hansen L.A., and Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox. Res. 8 (2005) 51-61
92. Factor S.A., Podskalny G.D., and Barron K.D. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J. Neurol. Sci. 127 (1994) 114-120
93. Fang Y., and Ronnekleiv O.K. Cocaine upregulates the dopamine transporter in fetal rhesus monkey brain. J. Neurosci. 19 (1999) 8966-8978
94. Fawzi W.W., Msamanga G.I., Spiegelman D., Wei R., Kapiga E., Villamor E., Mwakagile F., Mugusi F., Hertzmark E., Essex M., and Hunter D.J. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N. Engl. J. Med. 351 (2004) 23-32
95. Fiala M., Eshleman A.J., Cashman J., Lin J., Lossinsky A.S., Suarez V., Yang W., Zhang J., Popik W., Singer E., Chiappelli F., Carro E., Weinand M., Witte M., and Arthos J. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J. Neurovirol. 11 (2005) 281-291
96. Fiala M., Gan X.H., Zhang L., House S.D., Newton T., Graves M.C., Shapshak P., Stins M., Kim K.S., Witte M., and Chang S.L. Cocaine enhances monocyte migration across the blood-brain barrier. Cocaine's connection to AIDS dementia and vasculitis?. Adv. Exp. Med. Biol. 437 (1998) 199-205
97. Filippi C.G., Ulug A.M., Ryan E., Ferrando S.J., and Van Gorp W. Diffusion tensor imaging of patients with HIV and normal-appearing white matter on MR images of the brain. Am. J. Neuroradiol. 22 (2001) 277-283
98. Fitting S., Booze R.M., and Mactutus C.F. Neonatal intrahippocampal gp120 injection: an examination early in development. Neurotoxicology 28 (2007) 101-107
99. Fitting S., Booze R.M., and Mactutus C.F. Neonatal intrahippocampal glycoprotein 120 injection: the role of dopaminergic alterations in prepulse inhibition in adult rats. J. Pharmacol. Exp. Ther. 318 (2006) 1352-1358
100. Fleckenstein A.E., Gibb J.W., and Hanson G.R. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406 (2000) 1-13
101. Fleckenstein A.E., Haughey H.M., Metzger R.R., Kokoshka J.M., Riddle E.L., Hanson J.E., Gibb J.W., and Hanson G.R. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur. J. Pharmacol. 382 (1999) 45-49
102. Flora G., Lee Y.W., Nath A., Hennig B., Maragos W., and Toborek M. Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain. Exp. Neurol. 179 (2003) 60-70
103. Floyd R.A., Hensley K., Jaffery F., Maidt L., Robinson K., Pye Q., and Stewart C. Increased oxidative stress brought on by pro-inflammatory cytokines in neurodegenerative processes and the protective role of nitrone-based free radical traps. Life Sci. 65 (1999) 1899-1983
104. Fosnaugh J.S., Bhat R.V., Yamagata K., Worley P.F., and Baraban J.M. Activation of arc, a putative "effector" immediate early gene, by cocaine in rat brain. J. Neurochem. 64 (1995) 2377-2380
105. Fujimura R.K., and Bockstahle L.E. Polymerase chain reaction method for determining ratios of human immunodeficiency virus proviral DNA to cellular genomic DNA in brain tissues of HIV-infected patients. J. Virol. Methods 55 (1995) 309-325
106. Fukami G., Hashimoto K., Koike K., Okamura N., Shimizu E., and Iyo M. Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. 1016 (2004) 90-95
107. Gainetdinov R.R., and Caron M.G. Monoamine transporters: from genes to behavior. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 261-284
108. Gavrilin M.A., Mathes L.E., and Podell M. Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J. Neurovirol. 8 (2002) 240-249
109. Gekker G., Hu S., Sheng W.S., Rock R.B., Lokensgard J.R., and Peterson P.K. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-β1. Int. Immunopharmacol. 6 (2006) 1029-1033
110. Gekker G., Hu S., Wentland M.P., Bidlack J.M., Lokensgard J.R., and Peterson P.K. Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J. Pharmacol. Exp. Ther. 309 (2004) 600-606
111. Gelman B.B., and Guinto F.C. Morphometry, histopathology, and tomography of cerebral atrophy in the acquired immunodeficiency syndrome. Ann. Neurol. 32 (1992) 31-40
112. Glass J.D., Wesselingh S.L., Selnes O.A., and McArthur J.C. Clinical-neuropathological correlation in HIV-associated dementia. Neurology 43 (1993) 2230-2237
113. Glowa J.R., Panlilio L.V., Brenneman D.E., Gozes I., Fridkin M., and Hill J.M. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570 (1992) 49-53
114. Goodkin K., Shapshak P., Metsch L.R., McCoy C.B., Crandall K.A., Kumar M., Fujimara R.K., McCoy V., Zhang B.T., Reyblat S., Xin K.Q., and Kumar A.M. Cocaine abuse and HIV-1 infection: epidemiology and neuropathogenesis. J. Neuroimmunol. 83 (1998) 88-101
115. Goodman J.H., and Sloviter R.S. Cocaine neurotoxicity and altered neuropeptide Y immunoreactivity in the rat hippocampus; a silver degeneration and immunocytochemical study. Brain Res. 616 (1993) 263-272
116. Grant I., Sacktor N., and McArthur J. HIV neurocognitive disorders. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 359-374
117. Grant I. The neurocognitive complications of HIV infection. In: Ramachandran V.S. (Ed). Encyclopedia of the Human Brain vol. 2 (2002), Academic Press, San Diego pp. 475-489
118. Grant I., and Atkinson J.H. Psychiatric aspects of acquired immune deficiency syndrome. In: Kaplan H.I., and Sadock B.J. (Eds). Comprehensive Textbook of Psychiatry vol. 6 (1995), Williams & Wilkins, Baltimore pp. 1644-1669
119. Grassi M.P., Perin C., Clerici F., Zocchetti C., Borella M., Cargnel A., and Mangoni A. Effects of HIV seropositivity and drug abuse on cognitive function. Eur. Neurol. 37 (1997) 48-52
120. Gray F., Scaravilli F., Everall I., Chretien F., An S., Boche D., Adle-Biassette H., Wingertsmann L., Durigon M., Hurtrel B., Chiodi F., Bell J., and Lantos P. Neuropathology of early HIV-1 infection. Brain Pathol. 6 (1996) 1-15
121. Gray F., Hurtrel M., and Hurtrel B. Early central nervous system changes in human immunodeficiency virus (HIV)-infection. Neuropathol. Appl. Neurobiol. 19 (1993) 3-9
122. Gray F., and Lescs M.C. HIV-related demyelinating disease. Eur. J. Med. 2 (1993) 89-96
123. Griffin III W.C., Middaugh L.D., and Tyor W.R. Chronic cocaine exposure in the SCID mouse model of HIV encephalitis. Brain Res. 1134 (2007) 214-219
124. Hall, M., Robertson, K.R., Smith, J.K., Aylward, S.R., Wilber, K., Lin, W., 2004. Neuroimaging in HIV infection. Presented at The NIMH/NIDA Meeting Molecular Markers and Mechanisms of HIV-Induced Nervous System Disease in Washington, DC.
125. Hanson G.R., Rau K.S., and Fleckenstein A.E. The methamphetamine experience: a NIDA partnership. Neuropharmacology 47 Suppl. 1 (2004) 92-100
126. Harakeh S., Jariwalla R.J., and Pauling L. Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 7245-7249
127. Hayman M., Arbuthnott G., and Harkiss G. Neurotoxicity of peptide analogues of the transactivating protein Tat from maedi-visna virus and human immunodeficiency virus. Neuroscience 53 (1993) 1-6
128. Hestad K., McArthur J.H., Dal Pan G.J., Selnes O.A., Nance-Sproson T.E., Aylward E., Mathews V.P., and McArthur J.C. Regional brain atrophy in HIV-1 infection: association with specific neuropsychological test performance. Acta Neurol. Scand. 88 (1993) 112-118
129. Hill J.M., Mervis R.F., Avidor R., Moody T.W., and Brenneman D.E. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res. 603 (1993) 222-233
130. Hinkin C.H., Castellon S.A., Hardy D.J., Farinpour R., Newton T., and Singer E. Methylphenidate improves HIV-1-associated cognitive slowing. J. Neuropsychiatr. Clin. Neurosci. 13 (2001) 248-254
131. Hitri A., Casanova M.F., Kleinman J.E., and Wyatt R.J. Fewer dopamine transporter receptors in the prefrontal cortex of cocaine users. Am. J. Psychiatry 151 (1994) 1074-1076
132. Hofman F.M., Wright A.D., Dohadwala M.M., Wong-Staal F., and Walker S.M. Exogenous Tat protein activates human endothelial cells. Blood 92 (1993) 2774-2780
133. Hollander H., Golden J., Mendelson T., and Cortland D. Extrapyramidal symptoms in AIDS patients given low-dose metoclopropamide or chlorpromazine. Lancet 2 (1985) 186
134. Hriso E., Kuhn T., Masdeu J., and Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am. J. Psychiatry 148 (1991) 1558-1561
135. Hudgens M.G., Longini Jr. I.M., Vanichseni S., Hu D.J., Kitayaporn D., Mock P.A., Halloran M.E., Satten G.A., Choopanya K., and Mastro T.D. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am. J. Epidemiol. 155 (2002) 159-168
136. Hudson L., Liu J., Nath A., Jones M., Raghavan R., Narayan O., Male D., and Everall I. Detection of the human immunodeficiency virus regulatory protein Tat in CNS tissues. J. Neurovirol. 6 (2000) 145-155
137. Hulgan T., Marrow J., D'Aquila R.T., Raffanti S., Morgan M., Robeiro P., and Haas D.W. Oxidant stress is increasing during treatment of human immunodeficiency virus infection. Clin. Infect. Dis. 37 (2003) 1711-1717
138. Imam S.Z., Newport G.D., Itzhak Y., Cadet J.L., Islam F., Slikker Jr. W., and Ali S.F. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76 (2001) 745-749
139. Isreal N., Gougerot-Pocidalo M.A., Aillet F., and Virelizier J.L. Redox status of cells influences constitutive or induced NF-kappaB translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J. Immunol. 149 (1992) 3386-3393
140. Itoh K., Mehraein P., and Weis S. Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol. (Berl.) 99 (2000) 376-384
141. Jakobsen J., Gyldensted C., Brun B., Bruhn P., Helweg-Larsen S., and Atrien-Soberg P. Cerebral ventricular enlargement related to neuropsychological measures in unselected AIDS patients. Acta Neurol. Scand. 79 (1989) 59-62
142. Jenuwein M., Scheller C., Neuen-Jacob E., Sopper S., Tatschner T., ter Meulen V., Riederer P., and Koutsilieri E. Dopamine deficits and regulation of cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys. J. Neurovirol. 10 (2004) 163-170
143. Jernigan T.L., Gamst A.C., Archibald S.L., Fennema-Notestine C., Mindt M.R., Marcotte T.L., Heaton R.K., Ellis R.J., and Grant I. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am. J. Psychiatry 162 (2005) 1461-1472
144. Johanson C.E., and Fischman M.W. The pharmacology of cocaine related to its abuse. Pharmacol. Rev. 41 (1989) 3-52
145. Jones M.V., Bell J.E., and Nath A. Immunolocalization of HIV envelope gp120 in HIV encephalitis with dementia. AIDS 14 (2000) 2709-2714
146. Kahlig K.M., Javitch J.A., and Galli A. Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier. J. Biol. Chem. 279 (2004) 8966-8975
147. Kalivas P.W., and Duffy P. Time course of extracellular dopamine and behavioral sensitization to coaine. I. Dopamine axon terminals. J. Neurosci. 13 (1993) 266-275
148. Kaplan E.H., and Heimer R.A. A model-based estimate of HIV infectivity via needle sharing. J. Acquir. Immune Defic. Syndr. 5 (1992) 1116-1118
149. Kandanearatchi A., Nath A., Lipton S.A., Masliah E., and Everall I.P. Protection against HIV-1 gp120 and HIV-1 Tat neurotoxicity. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 201-210
150. Kaul M., and Lipton S.A. Mechanisms of neuronal injury and death in HIV-1 dementia. Curr. HIV Res. 4 (2006) 307-318
151. Kendall S.L., Anderson C.F., Nath A., Turchan-Cholewo J., Land C.L., Mactutus C.F., and Booze R.M. Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism. BMC Neurosci. 6 (2005) 40. http://www.biomedcentral.com/ (available at: www.biomedcentral.com)
152. Keswani S.C., Jack C., Zhou C., and Hoke A. Establishment of a rodent model of HIV-associated sensory neuropathy. J. Neurosci. 26 (2006) 10299-10304
153. Ketzler S., Weis S., Huag H., and Budka H. Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol. 80 (1990) 92-94
154. Kidwell D.A., and Blank D.L. Environmental exposure-the stumbling block on hair testing. In: Kintz P. (Ed). Drug Testing in Hair (1996), CRC Press, New York pp. 17-68
155. King J.E., Eugenin E.A., Buckner C.M., and Berman J.W. HIV Tat and neurotoxicity. Microb. Infect. 8 (2006) 1347-1357
156. Klotman P.E., Rappaport J., Ray P., Kopp J.B., Franks R., Bruggeman L.A., and Notkins A.L. Transgenic models of HIV-1. AIDS 9 (1995) 313-324
157. Knapp W.P., Soares B.G., Farrel M., and Lima M.S. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst. Rev. (2007) CD003023
158. Kokoshka J.M., Vaughan R.A., Hanson G.R., and Fleckenstein A.E. Nature of methamphetamine-induced rapid and reversible changes in dopamine transporters. Eur. J. Pharmacol. 361 (1998) 269-275
159. Kolson D.L., Collman R., Hrin R., Balliet J.W., Laughlin M., McGann K.A., Debouck C., and Gonzales-Scarano F. Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation. J. Gen. Virol. 75 (1994) 1927-1934
160. Kolson D., Buchhalter J., Collman R., Hellmig B., Farrell C.F., Debouck C., and Gonzales-Scarano F. HIV-1 Tat alters normal organization of neurons and astrocytes in primary rodent brain cell cultures: RGD sequence dependence. AIDS Res. Hum. Retrov. 9 (1993) 677-685
161. Kontur P.J., Won L.A., Hoffmann P.C., and Heller A. Survival of developing dopaminergic neurons in reaggregate tissue culture following treatment with methamphetamine. Neurosci. Lett. 129 (1991) 254-258
162. Koutsilieri E., Scheller C., ter Meulen V., and Riederer P. Monoamine oxidase inhibition and CNS immunodeficiency infection. Neurotoxicology 25 (2004) 267-270
163. Koutsilieri E., Sopper S., Scheller C., ter Meulen V., and Riederer P. Involvement of dopamine in the progression of AIDS dementia complex. J. Neural Transm. 109 (2002) 399-410
164. Koutsilieri E., Sopper S., Scheller C., ter Meulen V., and Riederer P. Parkinsonism in HIV dementia. J. Neural Transm. 109 (2002) 767-775
165. Koutsilieri E., ter Meulen V., and Riederer P. Neurotransmission in HIV associated dementia: a short review. J. Neural Transm. 108 (2001) 767-775
166. Koutsilieri E., Gotz M.E., Sopper S., Sauer U., Demuth M., ter Meulen V., and Riederer P. Regulation of glutathione and cell toxicity following exposure to neurotropic substances and human immunodeficiency virus-1 in vitro. J. Neurovirol. 3 (1997) 342-349
167. Kruman I.I., Nath A., and Mattson M. HIV-1 Tat induces apoptosis of hippocampal neurons by a mechanism involving caspase activation, calcium overload, and oxidative stress. Exp. Neurol. 154 (1998) 276-288
168. Kuczenski R., Melega W.P., Cho A.K., and Segal D.S. Extracellular dopamine and amphetamine after systemic amphetamine administration: comparison to the behavioral response. J. Pharmacol. Exp. Ther. 282 (1997) 591-596
169. Kuljis R.O., Shapshak P., Rodriguez de al Vega P., Fujimara R., and Petito C.K. Increased density of neurons containing NADPH diaphorase/nitric oxide synthase in the cerebral cortex of patients with HIV-1 infection and drug abuse. J. NeuroAIDS 2 (2002) 19-36
170. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing antibody. Nature 393 (1998) 648-659
171. Lafrenie R.M., Wahl L.M., Epstein J.S., Hewlett I.K., Yamada K.M., and Dhawan S. HIV-1 Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells: a mechanism of HIV pathogenesis. J. Immunol. 156 (1996) 1638-1645
172. Langford D., Adame A., Grigorian A., Grant I., McCutchan J.A., Ellis R.J., Marcotte T.D., Masliah E., and HIV Neurobehavioral Research Center Group. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J. Acquir. Immune Defic. Syndr. 34 (2003) 467-474
173. i homeostasis and induce neurotoxicity in human embryonic neurons. Eur. J. Neurosci. 7 (1995) 2285-2293
174. Lattanzio Jr. F.A., Tiangco D., Osgood C., Beebe S., Kerry J., and Hargrave B.Y. Cocaine increases intracellular calcium and reactive oxygen species, depolarizes mitochondria, and activates genes associated with heart failure and remodeling. Cardiovasc. Toxicol. 5 (2005) 377-390
175. Laurier L.G., Corrigall W.A., and George S.R. Dopamine receptor density, sensitivity and mRNA levels are altered following self-administration of cocaine in the rat. Brain Res. 634 (1994) 31-40
176. Lee S.C., and Dickson D.W. Common immune pathways of neural injury and neurodegenerative disorders. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 85-92
177. Letchworth S.R., Nader M.A., Smith H.R., Friedman D.P., and Porrino L.J. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus mokeys. J. Neurosci. 21 (2001) 2799-2807
178. Levine S.R., Brust J.C., Futrell N., Brass L.M., Blake D., Fayad P., Schultz L.R., Millikan C.H., Ho K.L., and Welch K.M. A comparative study of the cerebrovascular complications of cocaine: alkaloidal versus hydrochloride-a review. Neurology 41 (1991) 1173-1177
179. Lewis W., Day B.J., and Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2 (2003) 812-822
180. Lile J.A. Pharmacological determinants of the reinforcing effects of psychostimulants: relation to agonist substitution treatment. Exp. Clin. Psychopharmacol. 14 (2006) 20-33
181. Little K.Y., Elmer L.W., Zhong H., Scheys J.O., and Zhang L. Cocaine induction of dopamine transporter trafficking to the plasma membrane. Mol. Pharmacol. 61 (2002) 436-445
182. Loder M.K., and Melikian H.E. The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J. Biol. Chem. 278 (2003) 22168-22174
183. Mactutus C.F., Herman A.S., and Booze R.M. Chronic intravenous model for studies of drug (ab)use in the pregnant and/or group housed rat: an initial study with cocaine. Neurotoxicol. Teratol. 16 (1994) 183-191
184. Malone S.B., and Osborne J.J. Improving treatment adherence in drug abusers who are HIV-positive. Lippincotts Case Manag. 5 (2000) 236-245
185. Maragos W.F., Tillman P., Jones M., Bruce-Keller A.J., Roth S., Bell J.E., and Nath A. Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 117 (2003) 43-53
186. Maragos W.F., Young K.L., Turchan J.T., Guseva M., Pauly J.R., Nath A., and Cass W.A. Human immunodeficiency virus-1 Tat protein and methamphetamine interact synergistically to impair striatal dopaminergic function. J. Neurochem. 83 (2002) 955-963
187. Markou A., Arroyo M., and Barry J. Effects of contingent and non-contingent cocaine on drug-seeking behavior measured using a second-order schedule of cocaine reinforcement in rats. Neuropsychopharmacology 168 (1999) 192-200
188. Masliah E. In vivo modeling of HIV-1 mediated neurodegeneration. Am. J. Pathol. 149 (1996) 745-750
189. Masliah E., Achim C.L., Ge N., DeTeresa R., Terry R.D., and Wiley C.A. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann. Neurol. 32 (1993) 31-329
190. Masliah E., Ge N., Morey M., DeTeresa R.M., Terry R.D., and Wiley C. Cortical dendritic pathology in HIV encephalitis. Lab. Invest. 66 (1992) 285-291
191. Masliah E., Ge N., Achim C.L., Hansen L.A., and Wiley C.A. Selective neuronal vulnerability in HIV encephalitis. J. Neuropathol. Exp. Neurol. 51 (1992) 585-593
192. Mattson M.P., Haughey N.J., and Nath A. Cell death in HIV dementia. Cell Death Differ. 12 Suppl. 1 (2005) 893-904
193. Mazzucchelli R., Amadio M., Curreli S., Denaro F., Bemis K., Reid W., Bryant J., Riva A., Galli M., and Zella D. Establishment of an ex vivo model of monocyte-derived macrophages differentiated from peripheral blood mononuclear cells (PBMCs) from HIV-1 transgenic rats. Mol. Immunol. 41 (2004) 979-984
194. McArthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., and Sacktor N. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol. 9 (2003) 205-221
195. McArthur J.C., and Grant I. HIV neurocognitive disorders. In: Gendelman, Lipton, Epstein, and Swindells (Eds). Neurology of AIDS (1998), Chapman and Hall Publishers, New York pp. 499-523
196. McArthur J.C., McClernon D.R., Cronin M.F., Nance-Sproson T.E., Saah A.J., St Clair M., and Lanier E.R. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann. Neurol. 42 (1997) 689-698
197. Melikian H.E., and Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 19 (1999) 7699-7710
198. Missale C., Fiorentini C., Busi C., Collo G., and Spano P.F. The NMDA/D1 receptor complex as a new target in drug development. Curr. Top. Med. Chem. 6 (2006) 801-808
199. Moffet J.R., Namboodiri M.A., Cangro C.B., and Neale J.H. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2 (1991) 131-134
200. Mollace V., Nottet H.S., Clayette P., Turco M.C., Muscoli C., Salvemini D., and Perno C.F. Oxidative stress and neuroAIDS: triggers, modulators, and novel antioxidants. Trends Neurosci. 24 (2001) 411-416
201. Mollace V., and Nistico G. Release of nitric oxide from astroglial cells: a key mechanism in neuroimmune disorders. Adv. Neuroimmunol. 5 (1995) 421-430
202. Mollace V., Colasanti M., Persichini T., Bagetta G., Lauro G.M., and Nistico G. HIV gp120 glycoprotein simulates the inducible isoform of NO synthase in human cultured astrocytoma cells. Biochem. Biophys. Res. Commun. 194 (1993) 439-445
203. Moore J.P., and Klasse P.J. Thermodynamic and kinetic analysis of sCD4-binding to HIV-1 virions and of gp120 dissociation. AIDS Res. Hum. Retrov. 8 (1992) 443-450
204. Moore R.J., Vinsant S.L., Nader M.A., Porrino L.J., and Friedman D.P. Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys. Synapse 30 (1998) 88-96
205. Nader M.A., and Czoty P.W. PET imaging of dopamine D2 receptors in monkey models of cocaine abuse: genetic predisposition versus environmental modulation. Am. J. Psychiatry 162 (2005) 1473-1482
206. Nader M.A., Daunais J.B., Moore T., Nader S.H., Moore R.J., Smith H.R., Friedman D.P., and Porrino L.J. Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: initial and chronic exposure. Neuropsychopharmacology 27 (2002) 35-46
207. Nair M.P., Schwartz S.A., Mahajan S.D., Tsiao C., Chawda R.P., Whitney R., Don Sykes B.B., and Hewitt R. Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J. Neuroimmunol. 157 (2004) 56-60
208. Nance C.L., and Shearer W.T. Is green tea good for HIV-1 infection?. J. Allergy Clin. Immunol. 112 (2003) 851-853
209. Nassogne M.C., Louahed J., Evrard P., and Courtoy P.J. Cocaine induces apoptosis in cortical neurons of fetal mice. J. Neurochem. 68 (1997) 2442-2450
210. Nath A., and Sacktor N. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 19 (2006) 358-361
211. Nath A., Hauser K.F., Wojna V., Booze R.M., Maragos W., Prendergast M., Cass W., and Turchan J.T. Molecular basis for interactions of HIV and drugs of abuse. J. Acquir. Immune Defic. Syndr. 31 (2002) S62-S69
212. Nath A., Maragos W.F., Avison M.J., Schmitt F.A., and Berger J.R. Acceleration of HIV dementia with methamphetamine and cocaine. J. Neurovirol. 7 (2001) 66-71
213. Nath A., Haughey N.J., Jones M., Anderson C., Bell J.E., and Geiger J.D. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. 47 (2000) 186-194
214. Nath A., Anderson C., Jones M., Maragos W.F., Booze R.M., Mactutus C.F., Bell J., Hauser K.F., and Mattson M. Neurotoxicity and dysfunction of dopaminergic systems associated with AIDS dementia. J. Psychopharmacol. 14 (2000) 222-227
215. Nath A., Booze R.M., Hauser K.F., Mactutus C.F., Bell J., Cass W.A., Maragos W., and Berger J.R. Critical questions for neuroscientists in interactions of drugs of abuse and HIV infection. NeuroAIDS (1999) 2. http://www.sciencemag.org/NAIDS (available at: www.sciencemag.org/NAIDS)
216. Nath A., and Geiger J. Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog. Neurobiol. 54 (1998) 19-33
217. Nath A., Psooy K., Martin C., Knudsen B., Magnuson D.S.K., Haughey N., and Geiger J.D. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 70 (1996) 1475-1480
218. Navia B.A. The AIDS dementia complex. In: Cummings J.L. (Ed). Subcortical Dementia (1990), Oxford University Press Inc., New York pp. 181-198
219. Navia B.A., Jordan B.D., and Price R.W. The AIDS dementia complex. I. Clinical features. Ann. Neurol. 19 (1986) 519-524
220. Navia B.A., Cho E.S., Petito C.K., and Price R.W. The AIDS dementia complex. II. Neuropathology. Ann. Neurol. 19 (1986) 525-535
221. NIDA, 2004. Drug Abuse and AIDS. NIDA InfoFacts, November 2004 (available at: www.drugabuse.gov).
222. Neuenburg J.K., Brodt H.R., Herndier B.G., Bickel M., Bacchetti P., Price R.W., Grant R.M., and Schlote W. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31 (2002) 171-177
223. Nottet H.S. The blood-brain barrier: monocyte and viral entry into the brain. In: Gendelman, Grant, Everall, Lipton, and Swindells (Eds). The Neurology of AIDS. 2nd ed. (2005), Oxford University Press, London pp. 155-161
224. Nottet H.S., Persidsky Y., Sasseville V.G., Nukuna A.N., Bock P., Zhai Q.H., Sharer L.R., McComb R.D., Swindells S., Soderland C., and Gendelman H.E. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J. Immunol. 156 (1996) 1284-1295
225. Novick D.M., Trigg H.L., Des Jarlais D.C., Friedman S.R., Vlahov D., and Kreek M.J. Cocaine injection and ethnicity in parental drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J. Med. Virol. 29 (1989) 181-185
226. Oh S.H., and Lim S.C. A rapid and transient ROS generation by cadmium triggers apoptosis via caspase-dependent pathway in HepG2 cells and this is inhibited through N-acetylcysteine-mediated catalase upregulation. Toxicol. Appl. Pharmacol. 212 (2006) 212-223
227. Pascual-Leone A., Dhuna A., and Anderson D.C. Cerebral atrophy in habitual cocaine abusers: a planimetric CT study. Neurology 4 (1991) 34-38
228. Paul R.H., Brickman A.M., Navia B., Hinkin C., Malloy P.F., Jefferson A.L., Cohen R.A., Tate D.F., and Flanigan T.P. Apathy is associated with volume of the nucleus accumbens in patients infected with HIV. J. Neuropsychiatr. Clin. Neurosci. 17 (2005) 167-171
229. Paul R.H., Cohen R.A., Navia B., and Tashima K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neurosci. Biobehav. Rev. 26 (2002) 353-359
230. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 3rd ed. (1997), Academic Press, CA
231. Peavy G., Jacobs D., Salmon D.P., Butters N., Delis D.C., Taylor M., Massman P., Stout J.C., Heindel W.C., Kirson D., Atkinson J.H., Chandler J.L., Grant I., and The HNRC Group. Verbal memory performance of patients with human immunodeficiency virus infection: evidence of subcortical dysfunction. J. Clin. Exp. Neuropsychol. 16 (1994) 508-523
232. Persidsky Y., Potula R., and Haorah J. Rodent model systems for studies of HIV-1 associated dementia. Neurotox. Res. 8 (2005) 91-106
233. Persidsky Y., Buttini M., Limoges J., Bock P., and Gendelman H.E. An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. J. Neurovirol. 3 (1997) 401-416
234. Persidsky Y., Limoges J., McComb R., Bock P., Baldwin T., Tyor W., Patil A., Nottet H.S., Epstein L., Gelbard H., Flanagan E., Reinhard J., Pirruccello S.J., and Gendelman H.E. Human immunodeficiency virus encephalitis in SCID mice. Am. J. Pathol. 149 (1996) 1027-1053
235. Peterhans E. Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. J. Nutr. 127 (1997) S962-S965
236. Peterson J.P., Roszler M., Jacobs I., and Wilner H.I. Neurovascular complications of cocaine abuse. J. Neuropsychiatr. Clin. Neurosci. 3 (1991) 143-149
237. Petito C.K., Kerza-Kwiatecki A.P., Gendelman H.E., McCarthy M., Nath A., Podack E.R., Shapshak P., and Wiley C.A. Review: neuronal injury in HIV infection. J. Neurovirol. 5 (1999) 327-341
238. Pierce C.R., and Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Rev. 25 (1997) 192-216
239. Pocernich C.B., Sultana R., Mohmmad-Abdul H., Nath A., and Butterfield A. HIV-dementia, Tat-induced oxidative stress, and antioxidant therapeutic considerations. Brain Res. Rev. 50 (2005) 14-26
240. Pomara N., Crandall D.T., Choi S.J., Johnson G., and Lim K.O. White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. Psychiatr. Res. Neuroimaging 106 (2001) 15-24
241. Poon H.F., Abdullah L., Mullan M.A., Mullan M.J., and Crawford F.C. Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. Neurochem. Int. 50 (2007) 69-73
242. Porrino L.J., Daunais J.B., Smith H.R., and Nader M.A. The expanding effects of cocaine: studies in a nonhuman primate model of cocaine self-administration. Neurosci. Biobehav. Rev. 27 (2004) 813-820
243. Porrino L.J., Lyons D., Miller M.D., Smith H.R., Friedman D.P., Daunais J.B., and Nader M.A. Metabolic mapping of the effects of cocaine during the initial phases of self-administration in the non-human primate. J. Neurosci. 22 (2002) 7687-7694
244. Potash M.J., Chao W., Bentsman G., Paris N., Saini M., Nitkiewicz J., Belem P., Sharer L., Brooks A.I., and Volsky D.J. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3760-3765
245. Potula R., Haorah J., Knipe B., Leibhart J., Chrastil J., Heilman D., Dou H., Reddy R., Ghorpade A., and Persidsky Y. Alcohol abuse enhances neuroinflammation and impairs immune responses in an animal model of human immunodeficiency virus-1 encephalitis. Am. J. Pathol. 168 (2006) 1335-1344
246. Price T.O., Ercal N., Nakaoke R., and Banks W.A. HIV-1 viral proteins pg120 and Tat induce oxidative stress in brain endothelial cells. Brain Res. 1045 (2005) 57-63
247. Pulliam L., West D., Haigwood N., and Swanson R.A. HIV-1 envelope gp120 alters astrocytes in human brain cultures. AIDS Res. Hum. Retrovir. 9 (1993) 439-444
248. Quinton M.S., and Yamamoto B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J. 8 (2006) E337-E347
249. Ray P.E., Liu X.H., Robinson L.R., Reid W., Xu L., Owens J.W., Jones O.D., Denaro F., Davis H.G., and Bryant J.L. A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy. Kidney Int. 63 (2003) 2242-2253
250. Reid W., Abdelwahab S., Sadowska M., Huso D., Neal A., Ahearn A., Bryant J., Gallo R.C., Lewis G.K., and Reitz M. HIV-1 transgenic rats develop T cell abnormalities. Virology 321 (2004) 111-119
251. Reid W., Sadowska M., Denaro F., Rao S., Foulke Jr. J., Hayes N., Jones O., Doodnauth D., Davis H., Sill A., O'Driscoll P., Huso D., Fouts T., Lewis G., Hill M., Kamin-Lewis R., Wei C., Ray P., Gallo R.C., Reitz M., and Bryant J. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl. Acad. Sci. 98 (2001) 9271-9276
252. Reyes M.G., Faraldi F., Senseng C.S., Flowers C., and Fariello R. Nigral degeneration in acquired immune deficiency syndrome (AIDS). Acta Neuropathol. (Berl.) 82 (1991) 39-44
253. Reynolds J.L., Mahajan S.D., Bindukumar B., Sykes D., Schwartz S.A., and Nair M.P. Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res. 1123 (2006) 226-236
254. Riddle E.L., Fleckenstein A.E., and Hanson G.R. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J. 8 (2006) E413-E418
255. Riddle E.L., Fleckenstein A.E., and Hanson G.R. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 7 (2005) E847-E851
256. Robinson T.E., and Kolb B. Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur. J. Neurosci. 11 (1999) 1598-1604
257. Robinson T.E., and Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 17 (1997) 8491-8497
258. Roth M.D., Whittaker K.M., Choi R., Tashkin D.P., and Baldwin G.C. Cocaine and sigma-1 receptors modulate HIV infection, chemokines receptors, and the HPA axis in the huPBL-SCID model. J. Leukoc. Biol. 78 (2005) 1198-11203
259. Russo R., Navarra M., Maiuolo J., Rotiroti D., Bagetta G., and Corasaniti M.T. 17beta-Estradiol protects SH-SY5Y cells against HIV-1 gp120-induced cell death: evidence for a role of estrogen receptors. Neurotoxicology 26 (2005) 905-913
260. Sacktor N., Lyles R.H., Skolasky R., Kleeberger C., Selnes O.A., Miller E.N., Becker J.T., Cohen B., McArthur J.C., and MACS. HIV-associated neurologic disease incidence changes: multicenter AIDS cohort study, 1990-1998. Neurology 56 (2001) 257-260
261. Sandoval V., Riddle E.L., Ugarte Y.V., Hanson G.R., and Fleckenstein A.E. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci. 21 (2001) 1413-1419
262. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., and Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6850-6855
263. Sawada S., Gowrishankar K., Kitamura R., Suzuki M., Suzuki G., Tahara S., and Koito A. Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in transgenic mice expressing T cell line-tropic HIV-1 receptors. J. Exp. Med. 187 (1998) 1439-1449
264. Schlaepfer T.E., Lancaster E., Heidbreder R., Strain E.C., Kosel M., Fisch H.U., and Pearlson G.D. Decreased frontal white-matter volume in chronic substance abuse. Int. J. Neuropsychopharmacol. 9 (2006) 147-153
265. Schuff N., Meyerhoff D.J., Mueller S., Chao L., Sacrey D.T., Laxer K., and Weiner M.W. N-Acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv. Exp. Med. Biol. 576 (2006) 241-262
266. Segal D.S., Kuczenski R., O'Neil M.L., Melega W.P., and Cho A.K. Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28 (2003) 1730-1740
267. Sekine Y., Ivo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., and Mori N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry 158 (2001) 1206-1214
268. Selnes O.A., Galai N., McArthur J.C., Cohn S., Royal W., Esposito D., and Vlahov D. HIV infection and cognition in intravenous drug users: long-term follow-up. Neurology 48 (1997) 223-230
269. Shah S.M., Shapshak P., Rivers J.E., Weatherby N.L., Xin K.Q., Stewart R.V., Chitwood D.D., Page J.B., Mash D.C., Vlahov D., and McCoy C.B. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: preliminary lab results. J. AIDS 11 (1996) 301-306
270. Shapshak P., Shah S., Weatherby N., McCoy C., Chiappelli F., Page B., Bandstra E., Metsch L., McCoy V., Bonney C., Fletcher M.A., Phanidasak K., Orlando A., Gardner B., Jeanty Y., Hearn L., and Mash D. Cocaine and cocaethylene accelerate HIV progression in African-American women. Proceedings of the 4th Conference of Retroviruses and Opportunistic Infections, January. Washington, DC (1997) 22-26
271. Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J. Subst. Abuse Treat. 32 (2007) 41-52
272. Shor-Posner G., Lecusay R., Morales G., Campa A., and Miguez-Burbano M.J. Neuroprotection in HIV-positive drug users: implications for antioxidant therapy. J. Acquir. Immune Defic. Syndr. 31 Suppl. 2 (2002) 84-88
273. Silvers J.M., Aksenova M.V., Aksenov M.Y., Mactutus C.F., and Booze R.M. Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 28 (2007) 1184-1190
274. Silvers J.M., Aksenov M.Y., Aksenova M.V., Beckley J., Olton P., Mactutus C.F., and Booze R.M. Dopaminergic marker proteins in the substantia nigra of HIV1-infected brains. J. Neurovirol. 12 (2006) 140-145
275. Sim M.E., Lyoo I.K., Streeter C.C., Covell J., Sarid-Segal O., Ciraulo D.A., Kim M.J., Kaufman M.J., Yurgelun-Todd D.A., and Renshaw P.F. Cerebellar gray matter volume correlates with duration of cocaine use in cocaine-dependent subjects. Neuropsychopharmacology 32 (2007) 2229-2237
276. Simmons M.L., Frondoza C.G., and Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45 (1991) 37-45
277. Sinclair E., Gray F., Ciardi A., and Scaravilli F. Immunohistochemical changes and PCR detection of HIV provirus DNA in brains of asymptomatic HIV-positive patients. J. Neuropathol. Exp. Neurol. 35 (1994) 43-50
278. Snyder S.H. Nitric oxide and neurons. Curr. Opin. Neurobiol. 2 (1992) 323-327
279. Sonsalla P.K., Giovanni A., Sieber B.A., Donne K.D., and Manzino L. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann. NY Acad. Sci. 648 (1992) 229-238
280. Sorensen J.L., Mascovich A., Wall T.L., DePhilippis D., Batki S.L., and Chesney M. Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 10 (1998) 297-312
281. Sorkina T., Hoover B.R., Zahniser N.R., and Sorkin A. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 6 (2005) 157-170
282. Sorkina T., Doolen S., Galperin E., Zahniser N.R., and Sorkin A. Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J. Biol. Chem. 278 (2003) 28274-28283
283. Sousa F.C., Gomes P.B., Macedo D.S., Marinho M.M., and Viana G.S. Early withdrawal from repeated cocaine administration upregulates muscarinic and dopaminergic D2-like receptors in rat neostriatum. Pharmacol. Biochem. Behav. 62 (1999) 15-20
284. Spitzenberger T.J., Heilman D., Diekmann C., Batrakova E.V., Kabanov A.V., Gendelman H.E., Elmquist W.F., and Persidsky Y. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J. Cereb. Blood Flow Metab. 27 (2007) 1033-1042
285. Sporer B., Linke R., Seelos K., Paul R., Klopstock T., and Pfister H.W. HIV-induced chorea: evidence for basal ganglia dysregulation by SPECT. J. Neurol. 252 (2005) 356-358
286. Sporer B., Paul R., Koedel U., Grimm R., Wick M., Goebel F.D., and Pfister H.W. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J. Infect. Dis. 178 (1998) 854-857
287. Stanwood G.D., Lucki I., and McGonigle P. Differential regulation of dopamine D2 and D3 receptors by chronic drug treatments. J. Pharmacol. Exp. Ther. 295 (2000) 1232-1240
288. Steiner J., Haughey N., Li W., Venkatesan A., Anderson C., Reid R., Malpica T., Pocernich C., Butterfield D.A., and Nath A. Oxidative stress and therapeutic approaches in HIV dementia. Antioxid. Redox Signal. 8 (2006) 2089-2100
289. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15 (1995) 4102-4108
290. Tanda G. Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence. Pharmacol. Res. 56 (2007) 406-417
291. Theodore S., Cass W.A., and Maragos W.F. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137 (2006) 925-935
292. Theodore S., Cass W.A., and Maragos W.F. Involvement of cytokines in human immunodeficiency virus-1 protein Tat and methamphetamine interactions in the striatum. Exp. Neurol. 199 (2006) 490-498
293. Thompson P.M., Hayashi K.M., Simon S.L., Geaga J.A., Hong M.S., Sui Y., Lee J.Y., Toga A.W., Ling W., and London E.D. Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 24 (2004) 6028-6036
294. Toborek M., Lee Y.W., Flora G., Pu H., Andras I.E., Wylegala E., Hennig B., and Nath A. Mechanisms of the blood-brain barrier disruption of HIV-1 infection. Cell. Mol. Neurobiol. 25 (2005) 181-199
295. Toneatto S., Finco O., van der Putten H., Abrignani S., and Annunziata P. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 13 (1999) 2343-2348
296. Tse W., Cersosimo M.G., Gracies J.M., Morgello S., Olanow C.W., and Koller W. Movement disorders and AIDS: a review. Parkinsonism Relat. Disord. 10 (2004) 323-334
297. Tucker K.A., Robertson K.R., Lin W., Smith K., An H., Chen Y., Aylward S.R., and Hall C.D. Neuroimaging in human immunodeficiency virus infection. J. Neuroimmunol. 157 (2004) 153-162
298. Turchan J., Pocernich C.B., Gairola C., Chauhan A., Schifitto G., Butterfield D.A., Buch S., Narayan O., Sinai A., Geiger J., Berger J.R., Elford H., and Nath A. Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants. Neurology 60 (2003) 307-314
299. Turchan J., Anderson C., Hauser K.F., Sun Q., Zhang J., Liu Y., Wise P.M., Kruman I., Maragos W., Mattson M.P., Booze R.M., and Nath A. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci. 2 (2001) 3
300. UNAIDS/WHO, 2007. AIDS Epidemic Update, December 2007 (available at: www.unaids.org).
301. Valcour V., and Shiramizu B. HIV-associated dementia, mitochondrial dysfunction, and oxidative stress. Mitochondrion 4 (2004) 119-129
302. van Dyck C.H., McMahon T.J., Rosen M.I., O'Malley S.S., O'Connor P.G., Lin C.H., Pearsall H.R., Woods S.W., and Kosten T.R. Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. J. Neuropsychiatr. Clin. Neurosci. 9 (1997) 29-36
303. Vaughan R.A., Parnas M.L., Gaffaney J.D., Lowe M.J., Wirtz S., Pham A., Reed B., Dutta S.M., Murray K.K., and Justice J.B. Affinity labeling the dopamine transporter ligand binding site. J. Neurosci. Methods 143 (2005) 33-40
304. Vigorito M., LaShomb A.L., and Chang S.L. Spatial learning and memory in HIV-1 transgenic rats. J. Neuroimmune Pharmacol. 2 (2007) 319-328
305. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 18 (1998) 419-427
306. Volkow N.D., Fowler J.S., Wang G.J., Hitzemann R., Logan J., Schlyer D.J., Dewey S.L., and Wolf A.P. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14 (1993) 169-177
307. Volkow N.D., Fowler J.S., Wolf A.P., Hitzemann R., Dewey S., Bendriem B., Alpert R., and Hoff A. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am. J. Psychiatry 148 (1991) 621-626
308. Von Giesen H.J., Adams O., Koller H., and Arendt G. Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease. J. Neurol. 252 (2005) 801-807
309. Von Giesen H.J., Wittsack H.J., Wenerski F., Koller H., Hefter H., and Arendt G. Basal ganglia metabolite abnormalities in minor motor disorders associated with human immunodeficiency virus type 1. Arch. Neurol. 58 (2001) 1281-1286
310. 1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59 (2006) 51-60
311. Wallace D.R. HIV neurotoxicity: potential therapeutic interventions. J. Biomed. Biotechnol. (2006). http://www.pubmedcentral.nih.gov/ Available online at: www.pubmedcentral.nih.gov/
312. Wang G.J., Chang L., Volkow N.D., Telang F., Logan J., Ernst T., and Fowler J.S. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127 (2004) 2452-2458
313. Westover A.N., McBride S., and Haley R.W. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch. Gen. Psychiatry 64 (2007) 495-502
314. Wiley C.A., and Achim C.L. Human immunodeficiency virus encephalitis and dementia. Ann. Neurol. 38 (1995) 559-560
315. Wiley C.A., Masliah E., Morey M., Lemere C., DeTeresa R., Grafe M., Hansen L., and Terry R. Neocortical damage during HIV infection. Ann. Neurol. 29 (1991) 651-657
316. Wilson J.M., and Kish S.J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci. 16 (1996) 3507-3510
317. Wilson M.E., Dimayuga F.O., Reed J.L., Curry T.E., Anderson C.F., Nath A., and Bruce-Keller A.J. Immune modulation by estrogens: role in CNS HIV-1 infection. Endocrine 29 (2006) 289-297
318. Withers N.W., Pulvirenti L., Koob G.F., and Gillin J.C. Cocaine abuse and dependence. J. Clin. Psychopharmacol. 15 (1995) 63-78
319. Wrona M.Z., Yang Z., Zhang F., and Dryhurst G. Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. NIDA Res. Monogr. 173 (1997) 146-174
320. Wu Y., Storey P., Cohen B.A., Epstein L.G., Endelman R.R., and Ragin A.B. Diffusion alterations in corpus callosum of patients with HIV. Am. J. Neuroradiol. 27 (2006) 656-660
321. Yadav A., Pati S., Nyugen A., Barabitskaja O., Mondal P., Anderson M., Gallo R.C., Huso D.L., and Reid W. HIV-1 transgenic rat CD4+ T cells develop decreased CD28 responsiveness and suboptimal Lck tyrosine dephosphorylation following activation. Virology 353 (2006) 357-365
322. Yamaguchi K., Honda M., Ikigai H., Hara Y., and Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antivir. Res. 53 (2002) 19-34
323. Zahniser N.R., Larson G.A., and Gerhardt G.A. In vivo dopamine clearance rate in rat striatum: regulation by extracellular dopamine concentration and dopamine transporter inhibitors. J. Pharmacol. Exp. Ther. 289 (1999) 266-277
324. Zaragoza A., ez-Fernandez C., Alvarez A.M., Andres D., and Cascales M. Effect of N-acetylcysteine and deferoxamine on endogenous antioxidant defense system gene expression in a rat hepatocyte model of cocaine cytotoxicity. Biochim. Biophys. Acta 1496 (2000) 183-195
325. Zauli G., Secchiero P., Rodella L., Gibellini D., Mirandola P., Mazzoni M., Milani D., Dowd D.R., Capitani S., and Vitale M. HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J. Biol. Chem. 275 (2000) 4159-4165
326. Zauli G., Gibellini D., Milani D., Mazzoni M., Borgatti P., LaPlaca M., and Capitani S. The human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial and neuronal cell lines from death by apoptosis. Cancer Res. 53 (1993) 4481-4485
327. Zhang L., Looney D., Taub D., Chang S.L., Way D., Witte M.H., Graves M.C., and Fiala M. Cocaine opens the blood-brain barrier to HIV-1 invasion. J. Neurovirol. 4 (1998) 619-626